FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891651688> ?p ?o ?g. }

• W2891651688 endingPage "458" @default.
• W2891651688 startingPage "449" @default.
• W2891651688 abstract "Results from large randomised controlled trials have shown that adding docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate cancer (PC) prolongs survival for those with metastatic disease and prolongs failure-free survival for those without. To date there has been no formal assessment of whether funding docetaxel in this setting represents an appropriate use of UK National Health Service (NHS) resources.To assess whether administering docetaxel to men with PC starting long-term hormone therapy is cost-effective in a UK setting.We modelled health outcomes and costs in the UK NHS using data collected within the STAMPEDE trial, which enrolled men with high-risk, locally advanced metastatic or recurrent PC starting first-line hormone therapy.SOC was hormone therapy for ≥2 yr and radiotherapy in some patients. Docetaxel (75mg/m2) was administered alongside SOC for six three-weekly cycles.The model generated lifetime predictions of costs, changes in survival duration, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs).The model predicted that docetaxel would extend survival (discounted quality-adjusted survival) by 0.89 yr (0.51) for metastatic PC and 0.78 yr (0.39) for nonmetastatic PC, and would be cost-effective in metastatic PC (ICER £5514/QALY vs SOC) and nonmetastatic PC (higher QALYs, lower costs vs SOC). Docetaxel remained cost-effective in nonmetastatic PC when the assumption of no survival advantage was modelled.Docetaxel is cost-effective among patients with nonmetastatic and metastatic PC in a UK setting. Clinicians should consider whether the evidence is now sufficiently compelling to support docetaxel use in patients with nonmetastatic PC, as the opportunity to offer docetaxel at hormone therapy initiation will be missed for some patients by the time more mature survival data are available.Starting docetaxel chemotherapy alongside hormone therapy represents a good use of UK National Health Service resources for patients with prostate cancer that is high risk or has spread to other parts of the body." @default.
• W2891651688 created "2018-09-27" @default.
• W2891651688 creator A5000156180 @default.
• W2891651688 creator A5002802780 @default.
• W2891651688 creator A5004315918 @default.
• W2891651688 creator A5007452018 @default.
• W2891651688 creator A5007868861 @default.
• W2891651688 creator A5011243657 @default.
• W2891651688 creator A5014097745 @default.
• W2891651688 creator A5017069926 @default.
• W2891651688 creator A5017488456 @default.
• W2891651688 creator A5018620241 @default.
• W2891651688 creator A5022329395 @default.
• W2891651688 creator A5025921361 @default.
• W2891651688 creator A5026115891 @default.
• W2891651688 creator A5029103949 @default.
• W2891651688 creator A5030105260 @default.
• W2891651688 creator A5032518609 @default.
• W2891651688 creator A5032719534 @default.
• W2891651688 creator A5033521569 @default.
• W2891651688 creator A5035824583 @default.
• W2891651688 creator A5039273695 @default.
• W2891651688 creator A5046914918 @default.
• W2891651688 creator A5048994559 @default.
• W2891651688 creator A5050931392 @default.
• W2891651688 creator A5056268762 @default.
• W2891651688 creator A5058682657 @default.
• W2891651688 creator A5059261043 @default.
• W2891651688 creator A5059810788 @default.
• W2891651688 creator A5060049178 @default.
• W2891651688 creator A5060916908 @default.
• W2891651688 creator A5060969562 @default.
• W2891651688 creator A5062742458 @default.
• W2891651688 creator A5064442357 @default.
• W2891651688 creator A5066122486 @default.
• W2891651688 creator A5067159224 @default.
• W2891651688 creator A5067871333 @default.
• W2891651688 creator A5075073881 @default.
• W2891651688 creator A5079820994 @default.
• W2891651688 creator A5079843750 @default.
• W2891651688 creator A5080770312 @default.
• W2891651688 creator A5081647937 @default.
• W2891651688 creator A5082736524 @default.
• W2891651688 creator A5086077558 @default.
• W2891651688 creator A5088218569 @default.
• W2891651688 creator A5090337382 @default.
• W2891651688 date "2018-12-01" @default.
• W2891651688 modified "2023-10-06" @default.
• W2891651688 title "Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness" @default.
• W2891651688 cites W166560170 @default.
• W2891651688 cites W1891435709 @default.
• W2891651688 cites W1994222210 @default.
• W2891651688 cites W2016006304 @default.
• W2891651688 cites W2055346449 @default.
• W2891651688 cites W2067665433 @default.
• W2891651688 cites W2126499930 @default.
• W2891651688 cites W2134699227 @default.
• W2891651688 cites W2142466432 @default.
• W2891651688 cites W2143025931 @default.
• W2891651688 cites W2150865892 @default.
• W2891651688 cites W2152151422 @default.
• W2891651688 cites W2153386196 @default.
• W2891651688 cites W2168242827 @default.
• W2891651688 cites W2176970460 @default.
• W2891651688 cites W2178183066 @default.
• W2891651688 cites W2210989209 @default.
• W2891651688 cites W2214621962 @default.
• W2891651688 cites W2308780747 @default.
• W2891651688 cites W2620746860 @default.
• W2891651688 cites W2664930764 @default.
• W2891651688 cites W220649472 @default.
• W2891651688 doi "https://doi.org/10.1016/j.euo.2018.06.004" @default.
• W2891651688 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6692495" @default.
• W2891651688 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31158087" @default.
• W2891651688 hasPublicationYear "2018" @default.
• W2891651688 type Work @default.
• W2891651688 sameAs 2891651688 @default.
• W2891651688 citedByCount "18" @default.
• W2891651688 countsByYear W28916516882019 @default.
• W2891651688 countsByYear W28916516882020 @default.
• W2891651688 countsByYear W28916516882021 @default.
• W2891651688 countsByYear W28916516882022 @default.
• W2891651688 crossrefType "journal-article" @default.
• W2891651688 hasAuthorship W2891651688A5000156180 @default.
• W2891651688 hasAuthorship W2891651688A5002802780 @default.
• W2891651688 hasAuthorship W2891651688A5004315918 @default.
• W2891651688 hasAuthorship W2891651688A5007452018 @default.
• W2891651688 hasAuthorship W2891651688A5007868861 @default.
• W2891651688 hasAuthorship W2891651688A5011243657 @default.
• W2891651688 hasAuthorship W2891651688A5014097745 @default.
• W2891651688 hasAuthorship W2891651688A5017069926 @default.
• W2891651688 hasAuthorship W2891651688A5017488456 @default.
• W2891651688 hasAuthorship W2891651688A5018620241 @default.
• W2891651688 hasAuthorship W2891651688A5022329395 @default.
• W2891651688 hasAuthorship W2891651688A5025921361 @default.
• W2891651688 hasAuthorship W2891651688A5026115891 @default.
• W2891651688 hasAuthorship W2891651688A5029103949 @default.
• W2891651688 hasAuthorship W2891651688A5030105260 @default.

• next